This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study
by Zacks Equity Research
Sigilon (SGTX) stock declines as the FDA puts a clinical hold on its early/mid-stage hemophilia A study that was evaluating its lead candidate SIG-001.
Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral
by Zacks Equity Research
Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.
AMRX vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMRX vs. ZTS: Which Stock Is the Better Value Option?
AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition
by Zacks Equity Research
AstraZeneca (AZN) obtains European Commission's permission for the acquisition of Alexion. The deal is expected to close in the third quarter of 2021.
Alpine (ALPN) Enters Immuno-Oncology Collaboration With Merck
by Zacks Equity Research
Alpine (ALPN) signs a collaboration and supply deal with Merck to evaluate ALPN-202 in combination with the latter's Keytruda for treating various types of cancer.
Pandemic Boosts Animal Health Spending: 4 Stocks to Buy
by Riya Anand
Stocks like PetIQ (PETQ), IDEXX Laboratories (IDXX), Phibro Animal Health (PAHC) and Zoetis (ZTS) offering animal health products and services make great picks for long term.
Novo Nordisk (NVO) Inks Deal to Develop Heart Failure Treatment
by Zacks Equity Research
Novo Nordisk (NVO) inks an exclusive license agreement with Heartseed Inc. to manufacture and commercialize the latter's HS-001, a cell therapy developed for the treatment of heart failure.
Omeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients
by Zacks Equity Research
Omeros (OMER) announces data on critically ill COVID-19 patients treated with lead candidate, narsoplimab.
Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed
by Zacks Equity Research
Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three months.
Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod
by Zacks Equity Research
The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.
Viatris (VTRS) Beats on Q1 Earnings & Sales, Announces Dividend
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings while sales surpass expectations. The company announces inaugural quarterly dividend.
AMRX or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beat estimates for both earnings and revenues in the first quarter of 2021.
Zoetis (ZTS) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 21.15% and 7.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases first-quarter 2021 results.
Top Stock Reports for Apple, Alphabet & BlackRock
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Alphabet (GOOGL), and BlackRock (BLK).
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AstraZeneca (AZN) Gets FTC Clearance for Alexion Acquisition
by Zacks Equity Research
AstraZeneca (AZN) obtains U.S. Federal Trade Commission's permission for the Alexion acquisition. The deal is expected to close in the third quarter of 2021.
Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU
by Zacks Equity Research
The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.
FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag
by Zacks Equity Research
The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.
Sanofi (SNY) Acquires Tidal to Aid mRNA-Based Research Platform
by Zacks Equity Research
Sanofi's (SNY) acquisition of Tidal Therapeutics for $160 million is set to aid innovative mRNA-based research platform with applications in oncology, immunology and other diseases.